Delphi advisor to AddLife in the offer of a leading Spanish orthopaedic and trauma surgery business

Delphi has advised AddLife AB (publ) (“AddLife”) and its subsidiary AddLife Development AB in the offer to acquire all the shares in MBA Incorporado S.L (“MBA”), which has been accepted by Alantra Private Equity that owns approximately 75 percent of the shares. The agreed purchase price for 100 percent of the equity amounts to EUR 111 million cash and signing of the sale and purchase agreement for all shares, as well as completion, is expected to take place in January 2022.

AddLife is an independent European player in Life Science that offers high-quality products, services and consulting to both the private and public sectors. AddLife has about 1,800 employees in around 70 operating subsidiaries, which operate under their own brands. The AddLife group has annual sales of approximately SEK 7.5 billion. AddLife is listed on the NASDAQ Stockholm stock exchange.

MBA is a leading independent orthopaedic surgery distributor with operations in Spain, Italy and Portugal. The company has a turnover of approximately EUR 67 million and around 285 employees. The main product areas are orthopaedic implants for hip, knee and shoulder reconstructions, as well as products and solutions intended mainly for spine surgery and neurosurgery, trauma and anaesthesia. The acquisition of MBA strengthens AddLife’s position in advanced surgery and is fully in line with its strategy of expanding into relevant niches in Europe.

Delphi has been lead counsel in the acquisition and cooperated with the law firms Garrigues in Spain and Portugal as well as Gianni & Origoni in Italy.

Delphi’s team mainly consisted of Fredrik Mörner as responsible partner with assistance from several other lawyers at Delphi.